Thanks, I wonder though if there is any further information from the company about preparation for the second phase III for BPH?
From what I read BPH is a 5 billion dollar market whereas prostate cancer 1 billion. Not to mention that in my mind cancer seems to be a tougher nut to crack compared to BPH.
Unless they think that they won't displace the alpha blockers and 5 alpha reductase inhibitors very much.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.